Author: admin

“Prominent players in this market include Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US)”

The global peritoneal dialysis market is set to grow from USD 9.58 billion in 2024 to USD 12.70 billion by 2029, reflecting a robust CAGR of 5.8%. This expansion is largely driven by the rising prevalence of chronic kidney disease (CKD), particularly among older populations, as well as a shift towards home-based treatment options. Notably, about 14% of U.S. adults are affected by CKD, with significant government support for peritoneal dialysis in countries like China, enhancing accessibility. Key players such as Baxter International, Fresenius Medical Care, and Medtronic are advancing technologies to improve patient care, yet the market faces challenges like underutilization in low-income regions and a critical shortage of skilled nephrologists. Emerging economies like India and Brazil present significant growth opportunities, especially with increased healthcare expenditure. The Asia Pacific region is anticipated to exhibit the highest growth, fueled by an aging population and enhanced healthcare accessibility initiatives. As the market evolves, innovations in dialysis equipment and telemedicine are likely to further improve patient management and treatment outcomes, positioning peritoneal dialysis as a pivotal component of kidney care.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=211750966

Browse in-depth TOC on “Peritoneal Dialysis Market“

241 – Tables

66 – Figures

252 – Pages

In this report, the peritoneal dialysis market has been segmented on the basis of offering, modality, disease indication, end user and region.

The peritoneal dialysis market is segmented into peritoneal dialysis machines, solution bags, catheters, transfer sets, other peritoneal dialysis products and services on the basis of offerings. Peritoneal dialysis solution bags accounted for the largest share of global PD market, as daily dialysis dictates the need for multiple bag consumption by every patient. In nature, as consumables, they require constant replenishment to meet demand and thus are constantly in high demand. Their very low cost and wide availability make them readily used in advanced and developing countries lacking the proper health facilities. CAPD, a “bag alone” service that uses solution bags without dependency on equipment, is another significant contributor to this market. PD machines, meanwhile, are expected to grow at the highest CAGR because of innovations that make treatment convenient enough to be done overnight with minimal intervention. In an era when patients and providers increasingly demand automated and home-based alternatives, APD machines are gaining tremendous popularity, especially in developed regions. Improved patient outcomes and increased awareness are further fuelling the demand for PD machines, putting the machinery in a great position to experience rapid market growth.

The peritoneal dialysis market is segmented into continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) on the basis of modality. Continuous Ambulatory Peritoneal Dialysis (CAPD) holds the largest market share of peritoneal dialysis market. CAPD is not expensive because, unlike hemodialysis, it does not require technical personnel or heavy machines, and long periods of hospitalization; thus, it is much less costly in contrast with the others when patients undergo treatment with them. Its cost-effectiveness makes CAPD an economically viable choice for both patients and health care systems. CAPD does indeed lower overhead costs that the healthcare facilities incur, especially in less developed regions with strained resources. With ready-to-use consumables like solution bags, CAPD smoothes the efficient use of healthcare resources for continuation of treatment. The cost burden on patients being much lower, health systems can use their resources much more effectively and thus reach a larger segment of the population in need. These cost benefits come coupled with the simplicity and autonomy that CAPD lends to patients, which have been mainly driving a continuous increasing trend in its adoption into a mainstay of the global peritoneal dialysis market.

The peritoneal dialysis market is segmented into end-stage renal disease, acute kidney injury and other disease on the basis of disease indication. End-stage renal disease holds the largest share in the global peritoneal dialysis market and expected to grow at the highest CAGR. Increasing incidence of diabetes and hypertension serve as some of the significant risk factors that contribute to renal failure. As the prevalence of these chronic conditions increases across different parts of the world, more people have been developing ESRD and requiring renal replacement therapies such as dialysis. Diabetes and hypertension may lead to chronic and progressive damage to the kidneys, hence the need for effective management options such as peritoneal dialysis. In comparison with in-center hemodialysis, this modality has an added advantage to the patient in that it allows home-based treatment, giving the patient more flexibility and choice.

The peritoneal dialysis market is segmented into home care settings, hospitals & independent dialysis centers and other end user on the basis of end user. Home care settings accounted for the largest share in the global peritoneal dialysis market and expected to grow at the highest CAGR. Home care for dialysis saves patients a lot of time and incurs lesser costs because frequent hospital visits can be very tiring for patients and also costly. With home dialysis, most of the costs associated with hospitals, such as transportation and facility fees, are washed away, and it becomes quite economical for patients and health care. Cost-effectiveness, is most important in managing chronic diseases like end-stage renal disease. Additionally, home care treatment schedule can be more flexible and adjusted to the individual needs, without the burden on the healthcare facilities or health care resources at large.

The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa and GCC Countries on the basis of geographic region. North America holds the largest share of the peritoneal dialysis market in 2023. North America, has a well-developed healthcare system that can be described as having high technology and extensive medical facilities. With these sorts of robust infrastructures, peritoneal dialysis services are thus delivered efficiently so that the patients are provided with good quality care and latest innovations in their treatment. Its hospitals and clinics are supplied with high-end apparatuses and facilities to ensure effective management and monitoring of dialysis procedures. Furthermore, the availability of well-trained care providers who specialize in nephrology increases the result outcome as they can handle various cases that are peculiar to individuals. Such an advanced healthcare scenario facilitates the adoption of peritoneal dialysis with the discovery and development of newer ideas since this continuously aids in improving the standards of treatment protocols and technologies. Over time, this creates patient-friendly therapies with improved quality of life, thus throwing North America in an even more dominant position in the global peritoneal dialysis market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=211750966

Prominent players in this market include Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), AMECATH (Egypt), Polymedicure (India), Huaren Pharmaceutical (China), AWAK Technologies (Singapore), Innovative Renal Care (US), Romsons (India), SSEM Mthembu Medical (Pty) Ltd (South Africa), Renax Biomedical Technology Co., Ltd (China), and Advin Health Care (India).

BAXTER INTERNATIONAL INC. (US):

Baxter has developed a strong brand as well as from highly clinically superior products, such as IV therapies and infusion pump solutions. R&D facilities for the group exist in Belgium, Sweden, India, Italy, Germany, China, Japan, and the US. In 2023, its kidney care division registered net sales in the amount of USD 4.453 million, and its contribution to the total revenue was 30.1%. In 2022, Baxter started strategic review to improve stockholder value by offering selling and carve-out opportunities. In January 2023, the company announced some key strategic steps; one of them was to spin out Kidney Care as an independent, standalone, and publicly traded kidney care company named Vantive. Baxter also agreed to simplify the company, adjust its supply chain to operate more efficiently, and consider alternatives for its BPS business. In August 2024, Carlyle agreed with the takeover of its Kidney Care segment by Baxter; that marked the end of creating Vantive. With these alterations, Baxter is focusing toward hospital solutions and connected care and is trying to make the business model streamlined through an aligned strategy that positions toward innovation and ultimately delivers value to the stakeholders.

FRESENIUS MEDICAL CARE AG (GERMANY):

Fresenius Medical Care is one of the largest peritoneal dialysis players in the world. The company differs according to its comprehensive portfolio of dialysis products, remarkable R&D, and presence around the globe. The company operates through 42 facilities in Asia Pacific, North America, Europe, Latin America, and Africa, keeping a focus on partnership and agreement to seek further opportunity. Fresenius puts emphasis on the advanced dialysis products of renal therapies in developing the treatments for kidney disease. This further reinforces its market position. It focuses on purchases and acquisitions as well, as in the case of acquiring InterWell Health in 2022, which guides the drive towards innovation. The company operated 4,116 dialysis clinics at year-end 2022. Fifteen percent of U.S. patients are being treated in a home setting, increasing to 25% by 2025. Fresenius invests its R&D in innovative products, regenerative medicines, and the use of digital technologies such as data analytics and remote monitoring to optimize dialysis care.

MEDTRONIC PLC (IRELAND):

Medtronic Plc has some of the world’s fastest-moving markets with a requirement for constant innovation in order to stay at the top. This brings about the focus of its R&D on advancing technology, improving existing products and developing less invasive solutions for emerging markets. The company participates in hundreds of clinical trials per year in order to meet the demand for clinical and economic evidence with a view to reducing costs for patients and their hospital stays. The company focuses on developing new therapies, extending the use of existing products, and co-operation with third parties to take advantage of innovation and improve the lives of patients. For instance, Medtronic in partnership with Davita launched Mozarc Medical an independent firm that would revolutionize kidney health through patient-centered technology solutions in April 2023.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/peritoneal-dialysis-market-211750966.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peritoneal Dialysis Market to Hit USD 12.70 Billion by 2029 with 5.8% CAGR | MarketsandMarkets™

“Prominent players in the Periodontal Disease Treatment market include, – DENTSPLY SIRONA Inc. (US), Envista Holdings Corporation (US), A-dec Inc. (US), J. MORITA CORP. (Japan), Straumann Group (Switzerland)”

The global periodontal disease treatment market is projected to reach USD 3.63 billion by 2030 from USD 2.58 billion in 2024, growing at a CAGR of 5.9% during the forecast period 2024-2030. In all the regions, the regulatory environment of the treatment of periodontal disease is focused primarily on safety and efficacy considerations concerning therapeutic products and procedures. In the United States, dental devices-including dental implants, lasers, and others-are regulated by the Food and Drug Administration (FDA), which validates that they meet rigid standards of safety before marketing. Such drugs, again, which include antibiotics and antiseptics, the FDA demands clinical evidence to prove the efficacy of such drugs in reducing periodontal pathogens, with secondary inflammation.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=84851649

Browse in-depth TOC on “Periodontal Disease Treatment Market“

300 – Tables

60 – Figures

320 – Pages

In the European region, the legal system involving drugs is the European Medicines Agency (EMA) and devices under the Medical Device Regulation (MDR). The EMA has been careful in ensuring that drugs on periodontal conditions are tested not only for their benefits but also for their risks. In contrast, the MDR has put in more severe directives following 2021, with enhanced safety surveillance for dental devices.

In other countries including Japan and India, agencies such as PMDA and CDSCO monitor approval processes of periodontal treatments. The local standards that these agencies enforce must meet international requirements, especially in advanced therapeutic practices involving the use of biomaterials and devices that help in minimally invasive surgery.

Based on disease type, the periodontal disease treatment market is segmented into Gingivitis, acute periodontitis, aggressive periodontitis and others. Among these, in 2023, gingivitis holds the largest share in the periodontal disease treatment market. Market share for gingivitis treatment is substantial in the broader periodontal disease treatment market, driven by the high prevalence of gingivitis globally. Gingivitis is a mild form of periodontal disease and cuts across a large percentage of the population mainly due to poor oral hygiene, lifestyles such as smoking, and health conditions, including diabetes. This high occurrence naturally generates high demand for preventive and therapeutic products, such as antiseptic mouthwashes, specific toothpastes, and dental scaling operations.

Based on treatment type, the periodontal disease treatment market is segmented into non-surgical treatment, flap surgery, soft tissue graft, bone grafting, guided tissue regeneration and other treatments. Among these the non-surgical treatment segment accounts for the largest share in the periodontal disease treatment market.

in 2023, non-surgical treatments hold the largest share in the treatment of periodontal disease owing to several different factors, including the patients’ preference for less invasive options, quicker recoveries, and cost-effectiveness. Generally, non-surgical intervention, such as scaling and root planning (deep cleaning), antimicrobial agents, and laser therapy usually hold a first line of defence to the management of periodontal disease discovered in its early stages. These treatments will control infection, remove plaque and tartar from below the gum line, and will promote healing without the need for surgery.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=84851649

Key players in the authentication and brand protection market are – DENTSPLY SIRONA Inc. (US), Envista Holdings Corporation (US), A-dec Inc. (US), J. MORITA CORP. (Japan), Straumann Group (Switzerland), BIOLASE, Inc. (US), BEGO GmbH & Co. KG (Germany), Ultradent Products, Inc. (US), Yoshida Dental MFG. Co., Ltd. (Japan), Nakanishi Inc. (Japan), DentalEZ, Inc. (US), Geistlich Pharma AG (Switzerland), Nova Instruments (UK), NewTom (Italy), Millennium Dental Technologies, Inc. (US), PreXion, Inc. (Japan), Brasseler USA (US), AMD Lasers (US), and Bien-Air Dental (US). These players focus on developing innovative authentication and brand protection technologies and offerings owing to the emergence of new application areas for authentication and brand protection. These players not only have a diverse and comprehensive product portfolio but also have a strong geographic presence. These companies offer several product offerings and have operations worldwide. They rely on their diversified product and R&D capabilities and service portfolios to increase their market share. These companies focus on contracts product launches, acquisitions, collaborations, and partnerships to strengthen their footprint through product innovations and extend their business reach.

DENTSPLY SIRONA INC:

DENTSPLY SIRONA Inc. is a key market player in the global dental care market and plays an important role in the periodontal disease treatment market. The company provides a variety of innovative dental solutions. Among these solutions, the company has a specific product line for the care of periodontal diseases. Given the advancements in technologies and, therefore, a comprehensive portfolio of products, Dentsply Sirona provides solutions for periodontal scaling, root planning, and maintenance therapy, all of which are critical to the effective management of periodontal diseases.

Dentsply Sirona will continue to play an increasingly vital role in promoting treatment options for periodontal treatments, enhancing the outcomes of patients, and supporting dental professionals in achieving efficient and effective work through its robust global distribution network, strategic partnerships, and focusing research and development.

INSTITUT STRAUMANN AG (SWITZERLAND):

Institut Straumann, a global leader in dental implantology and restorative dentistry, has been actively involved in the periodontal disease treatment market. The company offers a range of innovative solutions, including regenerative products, which are designed to enhance periodontal regeneration and promote healing in patients with periodontal disease. Straumann’s portfolio includes biomaterials, such as bone grafts and membranes, which are critical in periodontal surgeries to restore lost bone and tissue.

HENRY SCHEIN, INC. (US):

Henry Schein is an American company and a Fortune World’s Most Admired Company. It is the largest distributor of healthcare products and services in the world, with a presence in 32 countries. The company supplies a wide range of animal health, medical, and dental products to office-based healthcare professionals. They also offer equipment financing, practice management software, and other value-added services. Henry Schein is one of the leading players in the periodontal disease treatment market, offering an array of products and services to help the dental practitioner manage periodontal diseases. Among the world’s largest distributors of dental supplies, Henry Schein gives the dentist advanced instruments for his practice; these include, dental lasers, scaling instruments, and other regenerative materials that feature in all periodontal treatments. In addition, the firm maintains a comprehensive portfolio of pharmaceuticals and diagnostic products which assist in the early detection and treatment of periodontal disease.

Apart from products supply, Henry Schein’s focus on education and training of dental practitioners has created great relevance for the company in this market. All possible means of continuing education programs, workshops, and online resources through which a dental practitioner can acquire all information about the latest trends and best practices of treating periodontal care allow Henry Schein to become a one-stop solution that can help both general dentists and periodontists carry out effective treatment outcomes for patients suffering from periodontal disease.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/periodontal-disease-treatment-market-84851649.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Periodontal Disease Treatment Market to Hit USD 3.63 Billion by 2030 with 5.9% CAGR | MarketsandMarkets™